MedTrace Logo

GEN2 Directed Cancer Immunotherapy Trial

NCT04313868 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2024-11-06

No results posted yet for this study

Summary

Phase 1, non-randomized, open label dose escalation clinical trial evaluating the safety of GEN2 in participants with primary \& metastatic liver tumors.

Conditions

Interventions

DRUG

GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)

GEN2 is an investigational drug combining cytotoxic and immunotherapy.

Sponsors & Collaborators

  • GenVivo, Inc.

    lead INDUSTRY

Principal Investigators

  • Priscilla B Caguioa, MD · St. Luke's Medical Center - Quezon City

  • Maria Belen E Tamayo, MD · Makati Medical Center

  • John P Querol, MD · The Medical City

  • Necy S Juat, MD · National Kidney and Transplant Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-13
Primary Completion
2023-12-12
Completion
2023-12-12

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04313868 on ClinicalTrials.gov